返回
杨
杨柳 (Yang Liu)
sichuan university
41H指数
497论文数
6.1K被引数
收录论文 116
发表时间
Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 study☆帕博利珠单抗联合恩扎卢胺和雄激素剥夺疗法与安慰剂联合恩扎卢胺和雄激素剥夺疗法治疗转移性激素敏感性前列腺癌:随机、双盲、III期KEYNOTE-991研究☆
Annals of Oncology
IF65.4
CYP11A1 inhibitor opevesostat (MK-5684) alone or in combination with other therapies for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): The phase I/II MK-5684-01A substudyCYP11A1抑制剂opevesostat(MK-5684)单药或联合其他疗法治疗转移性去势抵抗性前列腺癌(mCRPC)患者的I/II期MK-5684-01A亚组研究
ANNALS OF ONCOLOGY
IF65.4

